Identification and characterization of CD8 + and CD4 +
13. These responses were directed against dominant and subdominant epitopes representing all vaccine regions; Gag, Pol and Nef. Interestingly, IL-2 and IL-13 produced by CD4 + T cells were negatively correlated with the peak of viral replication following analytic treatment interruption (ATI). Epitope mapping confirmed that vaccination elicited responses against predicted T-cell epitopes, but also allowed to identify a set of 8 new HIV-1 HLA-DRrestricted CD4 + T-cell epitopes. These results may help to better design future DC therapeutic vaccines and underscore the role of vaccine-elicited CD4 + T-cell responses to achieve control of HIV replication.
Author summary
Improvement of therapeutic vaccine strategies in the perspective of HIV cure is warranted and one of the determinant factors for elucidating the nature of protective cellular responses is the identification and characterization of CD8 + and CD4 + T-cell epitopes elicited by the vaccine. However, fine characterization of vaccine response at the level of 
Introduction
Globally, an estimated 36.9 million people were living with Human Immunodeficiency Virus (HIV) in 2017, among them 59% were accessing antiretroviral therapy [1] . Introduction of combination antiretroviral therapy (cART) since the late 1990's decreased HIV-related morbidity and mortality [2] and reduced the risk of HIV transmission [3] . However, cART requires a life-long adherence to treatment, has potential long-term side-effects [4] , and poor adherence can result in the development of resistance [5] . HIV infection has also been shown to result in more prevalent age-associated non-communicable comorbidities like peripheral arterial, cardiovascular disease, and impaired renal function as compared to HIV-uninfected controls [6] . Furthermore, among well-treated HIV-infected individuals � 50 years without comorbidity or AIDS-defining events, the estimated median survival time remains lower than in the general population [7] . Importantly, cART is not able to eradicate HIV infection and the virus persists in long-lived reservoir cells [8] leading to the inevitable rebound of HIV within few days following cART interruption [9] . Thus, strengthened by recent scientific advances, the field is focused on development of strategies able to improve the immune control of HIV replication and to prolong the period of remission (i.e. HIV control without cART) leading to improvement of quality of life, decrease in morbidity and sparing costs.
Vaccines are essential elements of these functional cure strategies. The rationale of therapeutic immunization relies on the induction of HIV-specific cellular responses through the improvement of the magnitude of preexisting T-cell immune responses elicited by the natural infection which are not able to control HIV replication [10] . A common endpoint in vaccine trials is measurement of the breadth and magnitude of vaccine-induced CD4 + and CD8 + Tcell responses. Identification and characterization of CD8 + and CD4 + T-cell epitopes, as well as the restricting HLA alleles can play a major role in elucidating the nature of protective cellular responses and mechanism of the immune evasion of HIV. CD8 + T-cell epitopes are typically 8-11-mer peptides restricted by HLA class I [11] and CD4 + T-cell epitopes are 12-20-mer peptides restricted by HLA class II [12] . A large number of HIV epitopes have been identified and deposited into various databases. The growing amount of class-I and class-II HLA / peptide-binding data generated by experimental methods has supported the generation of more sophisticated, computational tools which can predict CD8 + and CD4 + T-cell epitopes within viral proteomes by using different data-driven bioinformatic approaches including Artificial Neural Network (ANN), Support Vector Machines, hidden Markov models, as well as other motif search algorithms. Using these HLA binding predictors can improve the efficiency of epitope mapping protocols in vaccine trials [13] . To achieve an optimal effect of therapeutic vaccination, the choice of antigens and vector is of critical importance. Several HIV-1 therapeutic candidate vaccines are currently under evaluation and one particularly considered approach is the use of dendritic cell (DC)-based vaccines [14] . Indeed, since DCs are the most powerful antigen-presenting cells (APCs) to initiate generation of antigen-specific CD4 + and CD8 + T-cell responses [15] , it has been suggested that ex vivo-gener- [19] . We have shown that DALIA vaccination was well tolerated and increased the breadth and functionality of HIV-1 specific immune responses. Moreover, the DALIA study design included a 6-month analytic treatment interruption (ATI) which allowed to show an inverse correlation between the peak of viral load after ATI and the frequency of polyfunctional CD4 + T-cell responses after vaccination [20] .
In the present study, we performed more in-depth epitope mapping to dissect anti-HIV-1 specific immune responses in order to better characterize vaccine responses associated with the control of viral load post-ATI. We showed that viral control was associated with the breadth and magnitude of IL-2 and IL-13 CD4 + T-cell responses targeting both immunodominant and subdominant HIV-1 peptides included in Gag, Pol and Nef vaccine regions. These results highlight the potential use of IL-13 as a new biomarker of HIV-1 vaccine efficacy and may help to better design the future DC therapeutic vaccine trials.
Results

DALIA vaccine regimen broadened breadth of HIV-specific immune responses
We previously showed that DALIA DC-based therapeutic vaccination (see Materials and Methods section and S1 Fig for study design) induced and increased HIV-1 specific CD4 + and CD8 + T-cell immune responses and a broad repertoire of cytokine producing cells [20] . To better characterize these responses, we analyzed the production of cytokines before (W-4) and after (W16) vaccination in PBMCs stimulated with individual 15-mer peptides (overlapping by 11 amino acids) spanning the LIPO-5 vaccine regions using Luminex technology. Positive responses were defined as production of at least one detectable cytokine following individual peptide stimulation (see Materials and Methods section and S1 Table) . As shown in Fig 1A, at W16 a production of cytokines was observed in a higher proportion of patients as compared to baseline; IFNγ (94% at W16 / 56% at baseline), IL-2 (94% / 19%, p<0.05), IL-13 (75% / 6%, p<0.05), IL-21 (63% / 0%, p<0.05) and IP-10 (81% / 31%). As shown in Fig 1B, vaccination also significantly increased the breadth of responses. At baseline, the median number of epitopes inducing the production of at least one cytokine (IFNγ, IL-2, IL-10, IL-13, IL-17, IL-21 or IP-10) were between 0-1 (range 0-7). After vaccination, these numbers were significantly increased (p<0.05) for IFNγ, IL-2, IL-13, IL-21 and IP-10 (median between 1.5-7.5, range 0-28). In contrast, neither IL-10 nor IL-17 responses were significantly increased after vaccination (Fig 1A and 1B) . Thus, DALIA vaccine regimen broadened breadth and improved functionality of HIV-specific immune responses targeting vaccine regions.
Vaccine-elicited cytokine responses are associated with lower viral load following cART interruption RNA in patients following cART interruption. We found an inverse correlation (Spearman) between the maximum of plasma HIV RNA values and the number of peptides eliciting IL-2 (r = -0.58, P = 0.020), and IL-13 (r = -0.66, P = 0.007) production, and the magnitude of the response for IFNγ (r = -0.51, P = 0.047), IL-2 (r = -0.66, P = 0.007) and IL-13 (r = -0.71, P = 0.003). No correlation was observed for IL-21 or IP-10 ( Fig 1C) . These results showed an association between the breadth and magnitude of vaccine-elicited functional responses at W16 and a lower viral rebound following ATI post vaccination.
Identification of immunodominant HIV responses induced by the vaccine
Next, we sought to characterize peptide-specific IFNγ, IL-2 and IL-13 responses further, since they were significantly associated with lower viral load after ATI. Before vaccination (W-4), only a weak cytokine secretion was observed (S2 Fig). After vaccination (W16), we observed that each peptide induced a similar polyfunctional cytokine profile (Fig 2A) and that 6 peptides (Gag17-2, Gag253-3, Gag253-4, Gag253-5, Gag253-6, Pol325-5) induced a stronger response in at least half of the patients, either in FI (Fig 2A) or in concentration (Fig 2B) . These immunodominant peptides were derived from the HIV-1 Gag and Pol vaccine sequences and not from Nef. Individual concentration data for all peptide stimulations are provided in S2 Table. No secretion of IFN-γ, IL-2 and IL-13 after vaccination was observed with non-stimulated PBMC or PBMC stimulated with non-vaccine-specific HIV-1 peptides (pools of 15-mer overlapping peptides from p2p6 Gag, outside the vaccine sequence) and high secretion of these cytokines was observed using SEB stimulation (S3 Fig) . 
Identification of targeted peptides associated with lower viral load following cART interruption
We then investigated whether peptide-specific secretion of IFNγ, IL-2 and IL-13 cytokines observed after vaccination (W16) could be associated with viral dynamics after ATI. Thus, we correlated the magnitude of cytokine responses to the 36 individually tested peptides with the maximum viral load detected following cART interruption. For eighteen peptides, an inverse correlation (Spearman) between the maximum of HIV RNA values and magnitude of the specific response for at least one cytokine was found (Fig 2C, peptides in bold) . All of them, except N116-8, passed positivity criteria described in Methods section (labeled with � ). Thus, responses elicited by the vaccination against 17 peptides of interest from Gag, Nef and Pol proteins were identified as potentially associated with control of viral load post-ATI. Interestingly, there was an overlap with 3 (Gag253-3, Gag253-4, Pol325-5) of the 6 immunodominant peptides previously identified in Fig 2A and 2B (highlighted within red rectangles) . T-cell responses (Table 1 and S3 Table) . These epitopes were localized in HIV-1 Gag, Nef and Pol vaccine sequences. Interestingly, 3 of them were immunodominant (Gag17-2, Gag253-3 and Pol325-5) and 5 of them were associated with a lower viral rebound after ATI (Gag253-3, Nef66-5, Nef66-6, Pol325-5, and Pol325-8). responses observed and predicted, we used 8-to 10-mer peptides in ICS assays to identify the optimal CD8 + T-cell epitopes. A total of 30 CD8 + T-cell responses were identified (79%) of which 6 (20%) were directed towards an epitope shared by two different 15-mer peptides. So 24 unique IFNγ-positive CD8 + T-cell responses were observed, leading to the identification of a total of 18 different well-described CD8 + T-cell epitopes (Table 2) .
Identification of HIV-specific cytokine-producing T cells
Thus, DALIA vaccine regimen induced more CD4 + than CD8 + T-cell responses and 8 new HIV-1 HLA-DR-restricted CD4 + T-cell epitopes with their restricting HLA-DRB1 allele were identified. association between these responses and the control of HIV replication in patients following ATI. One limitation of our study is the lack of demonstration of the real killing capacity of these cells, which was precluded for technical reasons. Nevertheless, assuming that it is likely that a therapeutic epitope-based vaccine certainly needs to contain different CD8 + T-cell epitopes able to bind many different HLA haplotypes, in order to circumvent HIV-1 mutations, our data demonstrate that our DALIA platform is an efficient immunogenic vaccine strategy. Moreover, these data reinforce the need to combine immunotherapeutic strategies along with a vaccine to achieve a functional control of HIV replication. We extended this repertoire by identification of 6 immunodominant 15-mer peptides elicited after DALIA vaccination: Gag17-2 (EKIRLRPGGKKKYKL), Gag253-3 (PVGEIYKRWIIL GLN), Gag253-4 (IYKRWIILGLNKIVR), Gag253-5 (WIILGLKNIVRMYSP), Gag253-6 (GLNKIVRMYSPTSIL) and Pol325-5 (EPFRKQNPDIVIYQY). The first five were already described as CD4 + T-cell epitopes [53] and listed in the HIV molecular immunology database (http://www.hiv.lanl.gov/content/immunology/tables/helper_summary.html). Gag253-3, Gag253-4, Gag253-5 and Gag253-6 have been described as DRB1 � 04:01 restricted epitopes in a study using HLA DR4 transgenic mice [54] . Gag253-4, Gag253-5 and Gag253-6 were also found to be promiscuous peptides, i.e. able to bind multiple HLA-DR alleles, using NetMHCIIpan 3.2, the server we used to predict binding of 15-mer peptides to HLA Class II DRB1 alleles. Pol325-5 was not listed in the HIV molecular immunology database, nonetheless it is nearly totally contained (93% overlap) in a Pol CD4 + T-cell promiscuous epitope identified by van der Burg and colleagues [55] . Of note, in some studies where the breadth of Gag-specific CD4 + T-cell responses was shown to be associated with lower viral load in HIV-infected individuals [56-58], Gag17-4, Gag253-4, Gag253-5, Gag253-6 and Gag253-7 were the main targeted epitopes. HIV-1 Nef-specific CD4 + T-cell responses are also important to control HIV-1 viral load and the Nef 66-97 peptide included in the DALIA vaccine was found among the 4 Nef epitopes previously associated with non-progression in HIV-1 infection [59] . In our study, we found that responses to seventeen 15-mer peptides of interest were potentially associated with lower viral load after ATI. Among them, Gag253-4 and Nef66-6 CD4 + T-cell epitopes were found in the studies mentioned above. All these data suggest that Gag253-4 is probably the most important HIV-1 sequence to be included in a therapeutic vaccine, and this is strengthened by its large capacity to bind to the 20 most frequent HLA-DRB1 alleles in the world population [60] .
To study the reliability of the epitope prediction servers used in our study, we first looked whether the observed responses were predicted. Among the 117 cytokine-positive CD4 + T-cell responses detected in our study, only 35% were predicted to bind DRB1 molecules by NetMHCIIpan 3.2 server, but it is difficult to comment on the reliability of NetMHCIIpan 3.2 server because we only used HLA-DRB1 (and not HLA-DP or -DQ) molecules of the patients for epitope prediction with this server. By contrast, all 46 observed CD8 + T-cell responses were predicted to bind HLA class I A, B or C molecules of the patients by NetMHCpan 4.0 server. Then we looked whether the predicted responses were actually observed. Interestingly, only 10% of all predicted CD8 + T-cell responses were observed. A potential explanation could be that even the servers used in this study predict binding affinity of peptides to MHC molecules, affinity is only one of the determinant factors for a peptide to induce an immune response. Indeed, to be immunogenic, a peptide needs to be efficiently processed by the cell machinery and then presented by MHC molecules. Epitope flanking residues can influence the proteasome or peptidase processing of the antigen. TCR affinity for the peptide/MHC complex also has an important role on the induction of immune responses. For CD4 + T-cell responses, 51%
of predicted responses were observed and we found 3 different patterns: 1) some peptides were predicted to bind HLA-DR molecules frequently expressed by the patients and for those we observed the majority of CD4 + T-cell responses (this was the case for Gag253-4/5/6); 2) some peptides were predicted to bind HLA-DR frequently expressed by the patients and for those we observed only few CD4 + T-cell responses (this was the case for Gag17-4, Gag253-7 and Pol325-1/2); 3) some peptides were not predicted to bind HLA-DR molecules expressed by the patients, but for those we nevertheless observed a CD4 + T-cell responses (this was the case for Gag253-3, Nef66-4 and Pol325-4/5). This latter result could easily be explained by the fact that these peptides could bind HLA-DP or -DQ alleles. However, another explanation could be that HIV-1 regions that bind some HLA class II alleles very weakly can induce CD4 + T-cell responses, and this is actually the case for the HIV-1 lipopeptides used in the DALIA vaccine, for which the hierarchy of CD4 + T-cell epitopes relies on the frequency of pre-existing peptide-specific T cells in healthy donors [61] . Recently, an association of HLA-DRB1 allele expression with HIV viral load profiles at a population level was reported [62] . DRB1 � 15:02 was shown to be associated with HIV control whereas DRB1 � 03:01 was shown to be associated with HIV progression. Here, we identified using a modified ICS protocol with single HLA DRB1 transfected cell lines as APC, in vaccinated patients, 8 new HLA-DR CD4 + T-cell epitopes restricted by different HLA-DRB1 alleles.
Among them, Gag17-2 was restricted by DRB1 � 03:01. Although, in our study, due to the small number of patients, we could not find any effect of these two HLA-DRB1 alleles on viral load dynamics after ATI, prediction analysis revealed that only two epitopes Gag253-4 and Gag253-5 could bind the DRB1 � 03:01 allele while Gag253-4, Gag253-5, Gag253-6, Gag253-7, Pol325-1, Pol325-2 and Pol325-7 could bind the "protective" DRB1 � 15:02 allele. Our study has characterized epitope responses to a therapeutic HIV-1 vaccine beyond the "classical" analyses of responses to global HIV peptide pools. Our analysis benefited from the well described definition of HIV-1 peptides used for loading of the DC vaccine. This originality represents an advantage compared to similar studies using chemically or temperature inactivated whole autologous HIV or RNA-based pulsed DCs [42, 63, 64] . Regarding the need to significantly improve the breadth and the functionality of vaccine responses with the aim to better control HIV in the perspective of functional HIV cure, it is key to better identify the epitopes of interest. In contrast to several studies of these responses in natural infection, fine characterization of vaccine response at the level of individual peptides contained in therapeutic vaccine is lacking. We confirmed at the epitope level that the DALIA vaccine regimen induced CD8 + and CD4 + T-cell responses, and that IL-2 and IL-13 responses induced by the vaccine were mediated by CD4 + T cells. Beyond the dissection of precise epitopes, we described an inverse correlation between the breadth and magnitude of peculiar CD4 + T-cell responses producing IL-2 and/or IL-13 and a partial control of viral load after ATI. From a clinical stand point, these results may help to better design the future planned DC therapeutic vaccine trial. First, it is likely that a combined strategy to complement CD8 + T-cell responses (immune checkpoint blockers, cytokines such as IL-7 or IL-15) to CD4 + elicited Tcell responses is warranted. Second, a particular attention will be paid to IL-2 and IL-13 CD4 + T-cell responses in relation to viral load dynamics after ATI. Since DC-based vaccines are difficult to make and will be challenging to use on a large scale, a new generation of vaccines targeting DC in vivo was developed using monoclonal antibodies directed against cell-surface receptors [65] . Thus, the sequences of the 5 lipopeptides used in the DALIA vaccine were recently fused with an anti-human CD40 antibody to target DCs in vivo. Targeting DC of HIV-1 infected patients in vitro with this new candidate vaccine (αCD40.HIV5pep) showed induction of CD4 + T-cell responses towards Gag 253-284 and Pol 325-355 regions in a majority of patients [66] . Safety and immunogenicity of this vaccine construct administrated intradermally with poly-ICLC was recently demonstrated in rhesus macaques [67] . Moreover, in humanized mice infected with HIV-1 and treated with antiviral drugs, αCD40.HIV5pep plus poly-ICLC vaccination rescued HIV-1-specific CD4 + and CD8 + T-cell responses and reduced the size of the HIV-1 reservoir, leading to significant control of HIV-1 rebound after cART interruption [68] . Thus, either ex vivo (DALIA) and in vivo (anti-CD40.HIV5pep) DC-targeting platforms are promising immune interventions to combine with cytokines, immune checkpoint inhibitors, as well as broad neutralizing antibodies for an HIV cure [69] .
Materials and methods
Study design and vaccine preparation
The ANRS/VRI DALIA was a phase I single-center single-arm clinical trial (North Texas Infectious Diseases Consultants, Dallas, TX) sponsored by Baylor Institute for Immunology Research and the French Agency INSERM-Agence Nationale de Recherches sur le SIDA et les hepatites (INSERM-ANRS). Eligible participants were asymptomatic HIV-1-infected adults with CD4+ T cell counts >500 cells/μL and �25% of total lymphocytes, CD4 nadir �300 cells/ μL, and no history of AIDS-defining events. Participants had to be on combination antiretroviral therapy (cART) with plasma HIV RNA <50 copies/mL at screening and within the previous 3 months. Participants received four vaccinations at weeks (W) 0, 4, 8 and 12 while on cART. Participants who had HIV-1 RNA <400 copies/mL at W22 were proposed to interrupt cART at W24 until W48. Flowchart describing the ANRS/VRI DALIA clinical trial, as well as baseline characteristics of the patients, have been reported previously [20] and design of the DALIA trial is shown in S1 
Ethics statement
The trial was approved by the IRB of Baylor Research Institute (BRI) and registered on ClinicalTrials.gov (NCT00796770). All participants provided written informed consent.
HLA typing
Samples were sent to LABS Inc (Centennial CO, USA) for HLA Typing (A, B, C, DRB1 and DQB1) using High Resolution Sequence Based Testing (SBT). HLA characteristics of participants (A, B, and C for HLA class I and DRB1 for HLA class II) are reported in S4 Table.
Peptides used in T-cell assays
Fifteen-mer peptides (n = 36) overlapping by 11 amino acids (aa) and covering the vaccine sequences were synthesized by Biosynthesis (Lewisville, TX, USA) and used at a final concentration of 2 μM (sequences are listed in S1 Table) . Eight-to ten-mer peptides synthesized by NeoMPS (now PolyPeptide Laboratories France, Strasbourg) were used at 2 μg/ml to identify optimal CD8 + T-cell epitopes. was used to predict binding of peptides to MHC class-I (A, B and C) molecules of the participants and potential CD8 + T-cell epitopes. These prediction methods are based on ANN. For NetMHCIIpan 3.2, the prediction values are given in IC50 values (in nM) and as %Rank. The percentile rank for a peptide is generated by comparing its score against the scores of 200,000 random natural peptides of the same length of the query peptide. Strong and weak binding peptides are identified based on %Rank, with customizable thresholds. We applied the default thresholds of 2% and 10% for strong and weak binders, respectively. For NetMHCpan 4.0, the method is trained on a combination of more than 180,000 quantitative binding data and mass spectrometry derived MHC eluted ligands. Rank of the predicted affinity was compared to a set of random natural peptides. The peptide will be identified as a strong binder if the % Rank is below the specified threshold for the strong binders, by default 0.5%. The peptide will be identified as a weak binder if the % Rank is above the threshold of the strong binders but below the specified threshold for the weak binders, by default 2%.
Prediction of CD4 + and CD8 + T-cell epitopes
Luminex assay
Frozen PBMCs from aphereses before (W-4) and after (W16) vaccination were thawed and rested at 37˚C for 1h. Samples were filtered and resuspended in RPMI 1640 media supplemented with 10% Human serum (HS). Plates containing individual overlapping peptides, positive (Staphylococcal enterotoxin B (SEB)) and negative (no peptide) controls, were thawed at room temperature and 1x10 6 cells were added in each well to a final volume of 300 μl. After 48h of culture, the plates were centrifuged, and 200 μl of each supernatant was collected and frozen at -80˚C for cytokine detection. Measurements and analyses of secreted IL-2, IL-10, IL-13, IL-17, IL-21, IFNγ and IP10 (expressed in fluorescence intensity (FI) and concentration) were performed using an "in house" multiplex bead-based technology (Luminex) assay with a 
Intracellular Cytokine Staining (ICS)
Frozen PBMC from the apheresis at W16 were thawed and rested at 37˚C for 3h in RPMI 1640 media with L-Glutamax supplemented with Penicillin / Streptomycin and 10% HS (R-10HS). On day 0 (D0), 2x10 6 cells were cultured in 24 flat bottom wells culture plate with or without 2 μM of 15-mer peptides that induced a positive response by Luminex assay. IL-2 (10 U/ml) was added on day 2 and half of the volume of each culture well was refreshed with fresh media containing IL-2 (10 U/ml) at day 4. On day 7 the cells were divided in two 5 ml polypropylene tubes and washed two times. D0 non-stimulated cells were then stimulated or not with SEB, and D0 stimulated cells were re-stimulated or not with the same peptide as D0, in a 500 μl R-10HS final volume. Samples were analyzed with a BD LSRII and data were acquired with DIVA software. FlowJo 9.9.6 (TreeStar, Inc., Ashland, OR), Pestle 1.7 and Spice 5.35 (M. Roederer, National Institute of Health) softwares were used for data analysis.
Statistical analyses
For a given cytokine, a Luminex quantification was considered as a positive response if the fluorescence intensity (FI) was > 90 th percentile of all negative controls (non-stimulated cells before and after vaccination for all participants) and > 3 times the background (median of three negative control wells for the considered participant and time point 
